肝外胆管癌术后辅助放化疗治疗进展

Progress in postoperative adjuvant chemoradiotherapy for extrahepatic cholangiocarcinoma

肝外胆管癌(ECC)是一种恶性程度较高的肿瘤,即使在病变早期进行根治性切除手术,患者术后仍有较高的复发率,总体生存率低。近几年来,ECC术后辅助治疗的研究逐渐开展,以吉西他滨、氟尿嘧啶等为基础的辅助化疗或联合放、化疗可使ECC患者术后获益,延长患者的总生存期。然而现有的辅助治疗方案各异,缺少ECC术后辅助治疗的标准方案。本文结合最新发表的研究结果,讨论ECC术后辅助治疗的现状和主要措施。

Extrahepatic cholangiocarcinoma（ECC） is highly malignant. Even radical resection is performed in the early stage, ECC patients still have a high recurrence rate, with low overall survival. In recent years, clinical trials of postoperative adjuvant therapy have been carried out gradually. Adjuvant chemotherapy or combined chemoradiotherapy based on gemcitabine and fluorouracil have been shown beneficial for ECC patients after resection, prolonging the total survival of patients. However, the existing adjuvant therapy protocols are different, and there is no standard adjuvant therapy to recommend. This review discusses the status and main measures of postoperative adjuvant therapy for ECC, combined with the latest published findings.